40% drop on the news is way way overdone.
The drug has satisfied both primary point and safety, it is the interaction with BI's other drug MOA-B that cause the decision of discontinuation.
The key point is: the drug is working very well but just not with BI's scope.
Even if BI decide not to proceed the second (diabete) after the P2a mid next year, PXS will has the option to bring the drug to other Pharmas for new developments.
So the drug is NOT dead.
I don't see the reason of 40% drop on that news only, and I expect Gary is in the crisis control to speed up the LOXL2 deal
Strong rebounce on the way
40% drop on the news is way way overdone.The drug has satisfied...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $38.71M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 150000 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 416503 | 1 |
View Market Depth
| Last trade - 08.26am 06/09/2024 (20 minute delay) ? |
| SNT (ASX) Chart |
Day chart unavailable